CCO Annual Update
Lymphoma Annual Update 2005
Review the latest diagnostic advances and therapeutic regimens for specific lymphoma subtypes, including non-Hodgkin’s lymphoma and AIDS-related lymphoma.
Pathobiology of Non-Hodgkin’s Lymphoma: Recent Advances |
Module 1 of 11 |
|
Program Director: Julie M. Vose, MD
- Randy Gascoyne, MD, FRCPC
|
|
|
Topics covered include:
- Introduction
- Pathobiology of Follicular Lymphoma
- Cytogenetic Profile of Follicular Lymphoma
- The Role of Macrophages in Follicular Lymphoma
- Extranodal MALT Lymphomas
Learning Objectives
Upon completion of this activity, participants should be able to:
Review advances in gene expression profiling of various NHL subtypes. Understand key intracellular pathways associated with NHL. Describe genetic signatures associated with outcome and prognosis in NHL.
|
Update on Mantle Cell Lymphoma and Diffuse Large B-Cell Non-Hodgkin’s Lymphoma |
Module 2 of 11 |
|
Program Director: Julie M. Vose, MD
 
- Richard I. Fisher, MD
- Jonathan W. Friedberg, MD
|
|
|
Topics covered include:
- Introduction
- Rituximab for Mantle Cell Lymphoma
- HyperCVAD or ASCT After Standard Therapy for MCL
- Novel Approaches for the Treatment of MCL
- Diffuse Large B-Cell Lymphoma - Clinical Risk Stratification
Learning Objectives
Upon completion of this activity, participants should be able to:
Discuss novel treatments currently being evaluated in clinical trials for patients with diffuse large B-cell lymphoma and mantle cell lymphoma. Evaluate the use of rituximab in the treatment of diffuse large B-cell lymphoma. Review current therapeutic strategies for the treatment of mantle cell lymphoma.
|
Update on Lymphoma Management: Chronic Lymphocytic Leukemia |
Module 3 of 11 |
|
Program Director: Julie M. Vose, MD
|
|
Topics covered include:
- Introduction
- VHGene Mutation Status and ZAP-70 Expression as Prognostic Indicators
- Genomic Aberrations in CLL
- Combination Chemotherapy for CLL
- Chemotherapy Plus Rituximab
Learning Objectives
Upon completion of this activity, participants should be able to:
Recount the prognostic indicators of CLL. Review data describing treatment of chronic lymphocytic leukemia (CLL). Describe novel treatments being evaluated in patients with CLL.
|
Follicular NHL and Marginal Zone MALT-type Lymphomas |
Module 4 of 11 |
|
Program Director: Julie M. Vose, MD
|
|
Topics covered include:
- Introduction
- Improving Outcomes and Optimizing Treatment in FL Patients
- Rituximab Combinations in Follicular NHL
- Maintenance Rituximab: Prolonging Remission in Patients With Follicular Lymphoma
- Other Antibody Therapies for Follicular NHL
Learning Objectives
Upon completion of this activity, participants should be able to:
Review current therapeutic strategies for the treatment of follicular non-Hodgkin's and MALT-type lymphomas. Discuss novel treatments, including monoclonal antibodies, stem cell transplantation, radioimmunotherapy, and vaccine therapy, currently being evaluated in clinical trials for patients with follicular non-Hodgkin's lymphoma and MALT-type lymphomas. Evaluate the use of rituximab in the treatment of follicular non-Hodgkin's lymphoma.
|
Lymphomas and Hodgkin's Disease |
Module 5 of 11 |
|
Program Director: Julie M. Vose, MD
- Frederick B. Hagemeister, MD
|
|
|
Topics covered include:
- Introduction--Long-Term Treatment of Hodgkin's Lymphoma
- Classification of Hodgkin's Lymphoma
- Treatment of Early-Stage HL: ABVD Plus Radiation
- Treatment of Early-Stage HL: Chemotherapy Alone
- Classification of Early-Stage HL with Poor Prognostic Features
Learning Objectives
Upon completion of this activity, participants should be able to:
Review results of recent clinical trials for early-stage and advanced Hodgkin's lymphoma. Evaluate efficacy and safety of currently available therapy for Hodgkin's lymphoma. Describe strategies for management of relapsed Hodgkin's lymphoma, including treatment complications.
|
AIDS-related Lymphoma: Update 2005 |
Module 6 of 11 |
|
Program Director: Julie M. Vose, MD
|
|
Topics covered include:
- Introduction to AIDS-Related Lymphoma
- Impact of HAART on AIDS-related Lymphoma
- Etiology and Pathogenesis of AIDs-related Lymphoma
- Histopathology and Staging of ARLs
- Standard vs Low-Dose Chemotherapy for ARL
Learning Objectives
Upon completion of this activity, participants should be able to:
Discuss HAART’s impact on the decreasing incidence and improved survival of AIDS-related lymphoma. Describe the incidence, pathogenesis, and treatment of HIV-related Hodgkin’s disease. Review histopathology, staging, and prognostic indicators for AIDS-related lymphoma. Evaluate state-of-the-art treatment options for AIDS-related lymphoma.
|
Primary Central Nervous System Lymphoma |
Module 7 of 11 |
|
Program Director: Julie M. Vose, MD
|
|
Topics covered include:
- Introduction to Primary Central Nervous System Lymphoma
- Pathology of Primary Central Nervous System Lymphoma
- Clinical features of PCNSL
- Diagnostic Evaluation
- Diagnostic Evaluation: Neuroimaging
Learning Objectives
Upon completion of this activity, participants should be able to:
Evaluate the efficacy and safety of current treatments for PCNSL Discuss the presenting symptoms common for patients with primary central nervous system lymphoma (PCNSL) Review the current recommendations for diagnosing patients with PCNSL
|
Burkitt's and Associated Lymphomas |
Module 8 of 11 |
|
Program Director: Julie M. Vose, MD
|
|
Topics covered include:
- Introduction to Burkitt's Lymphoma
- Characteristics of Burkitt's Lymphoma
- CODOX-M/IVAC for Burkitt's Lymphoma
- HyperCVAD for Burkitt's Lymphoma
- Rituximab in Burkitt's Lymphoma
Learning Objectives
Upon completion of this activity, participants should be able to:
Describe prognostic features of Burkitt's lymphoma Discuss efficacy and safety of existing and new treatment options for Burkitt's lymphoma Review the difference of the biology of Burkitt's and Burkitt's-like lymphomas from other B-cell neoplasms
|
New Treatments for Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma |
Module 9 of 11 |
|
Program Director: Julie M. Vose, MD
 
- Francine Foss, MD, PhD, FACP
- Andrew J. Lipman, MD
|
|
|
Topics covered include:
- Introduction to T-Cell Lymphomas
- Treatment Overview for CTCL/PTCL
- Combination Chemotherapy for CTCL/PTCL
- Single-Agent Chemotherapy for CTCL/PTCL: Gemcitabine
- Single-Agent Chemotherapy for CTCL/PTCL: Liposomal Doxorubicin
Learning Objectives
Upon completion of this activity, participants should be able to:
Identify current strategies and approaches to managing cutaneous and peripheral T-cell lymphomas, including bone marrow and stem cell transplantation. Describe the role of novel agents, including targeted therapy and immunomodulatory agents, for the treatment of cutaneous and peripheral T-cell lymphomas. Review existing strategies for treating cutaneous and peripheral T-cell lymphomas.
|
Update on Radioimmunotherapy for Lymphoma |
Module 10 of 11 |
|
Program Director: Julie M. Vose, MD
 
- Robert S. Mocharnuk, MD
- Julie M. Vose, MD
|
|
|
Topics covered include:
- Introduction
- 131I Tositumomab as First-Line Treatment of FL
- 131I Tositumomab for Refractory FL
- 131I Tositumomab for Mantle Cell Lymphoma
- 90Y-Ibritumomab Tiuxetan as First-Line Treatment of FL
Learning Objectives
Upon completion of this activity, participants should be able to:
Discuss new agents and targets currently under development for NHL. Review the efficacy and toxicity of currently available radioimmunotherapy in the treatment of NHL. Describe the role of radioimmunotherapy agents in the treatment of patients with NHL.
|
Targeted and Novel Therapies for Non-Hodgkin's Lymphoma |
Module 11 of 11 |
|
Program Director: Julie M. Vose, MD
|
|
Topics covered include:
- Introduction
- Radioimmunotherapy for NHL
- Radioimmunotherapy With 131Iodine Tositumomab
- Radioimmunotherapy With 90-Yttrium Ibritumomab Tiuxetan
- Novel Monoclonal Antibodies
Learning Objectives
Upon completion of this activity, participants should be able to:
Discuss new agents and targets currently under development for NHL Review efficacy and toxicity of currently available radioimmunotherapy in the treatment of NHL Identify patient characteristics and lymphoma subtypes most likely to respond to particular radioimmunotherapy and targeted agents
|
Disclaimer:
The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
|